EYLEA® (English Alternative)

EYLEA® (aflibercept) is a prescription-only, intravitreal injectable medication designed for the treatment of various retinal vascular diseases. It is a recombinant fusion protein that acts as a VEGF inhibitor, targeting vascular endothelial growth factor-A (VEGF-A), VEGF-B, and placental growth factor (PlGF) to reduce abnormal blood vessel growth and fluid leakage in the eye. EYLEA® is indicated for conditions such as wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP). It is administered via intravitreal injection by a trained ophthalmologist.

EYLEA® must be administered by an eye care professional via intravitreal injection under aseptic conditions. The protocol varies depending on the indication.

• wAMD: 2 mg every month for the first 3 months, followed by 2 mg every 2 months.
  
• RVO: 2 mg monthly injections until visual and anatomic improvement is achieved.
  
• DME/DR: 2 mg monthly for 5 doses, then once every 2 months.
  
• ROP: 0.4 mg administered intravitreally in neonates.
  

EYLEA® is indicated for multiple retinal conditions but has specific contraindications and potential adverse effects.

Indications:

• Wet Age-related Macular Degeneration (wAMD)
  
• Macular edema following RVO
  
• Diabetic macular edema (DME)
  
• Diabetic retinopathy (DR)
  
• Retinopathy of prematurity (ROP)
  

Contraindications:

• Ocular or periocular infections
  
• Hypersensitivity to aflibercept or formulation components
  

Potential Side Effects:

• Common: Conjunctival hemorrhage, eye pain, vitreous floaters
  
• Serious: Endophthalmitis, retinal detachment, increased intraocular pressure
  

EYLEA® contains the following:

• Active ingredient: Aflibercept 40 mg/mL
  
• Inactive ingredients: Polysorbate 20, sodium phosphate monobasic, sodium phosphate dibasic, sodium chloride, sucrose, and water for injection
  

Each 0.05 mL intravitreal dose delivers 2 mg of aflibercept.

The EYLEA® package includes all necessary components for administration:

• 1 pre-filled sterile syringe (single-use)
  
• Each syringe contains 0.1 mL of solution, allowing extraction of a 0.05 mL dose
  
• Packaged in protective blister or tray, depending on region
  

Yes, EYLEA® has a range of potential side effects, mostly related to the intravitreal administration route.

• Common side effects:
  
  • Conjunctival hemorrhage (up to 25%)
    
  • Eye pain or discomfort
    
  • Vitreous detachment or floaters
    
• Serious side effects:
  
  • Intraocular inflammation
    
  • Endophthalmitis
    
  • Elevated intraocular pressure
    
  • Retinal detachment
    

Proper storage of EYLEA® is critical to maintain efficacy and safety.

• Storage temperature: 2°C to 8°C (refrigerated)
  
• Do not freeze
  
• Keep in original packaging to protect from light
  
• Shelf life: Refer to expiry date on packaging
  
• Single-use only – discard unused portion immediately after administratio